Glycogen storage disease type II other diagnostic studies: Difference between revisions
No edit summary |
No edit summary |
||
Line 22: | Line 22: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Gastroenterology]] | |||
[[Category:Pediatrics]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Genetic disorders]] | |||
[[Category:Metabolic disorders]] | |||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} |
Latest revision as of 19:41, 23 January 2018
Glycogen storage disease type II Microchapters |
Differentiating Glycogen storage disease type II from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type II other diagnostic studies On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type II other diagnostic studies |
FDA on Glycogen storage disease type II other diagnostic studies |
CDC on Glycogen storage disease type II other diagnostic studies |
Glycogen storage disease type II other diagnostic studies in the news |
Blogs on Glycogen storage disease type II other diagnostic studies |
Directions to Hospitals Treating Glycogen storage disease type II |
Risk calculators and risk factors for Glycogen storage disease type II other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Other diagnostic studies for glycogen storage disease type 2 (GSD type 2) include electromyography and molecular genetic testing. Electromyography findings suggestive of GSD type 2 include myopathy.
Other Diagnostic Studies
Electromyography
- Electromyography may be helpful in the diagnosis of glycogen storage disease type 2 (GSD type 2). Findings suggestive of GSD type 2 include:[1][2]
Molecular genetic testing
- Molecular genetic testing shows biallelic pathogenic variants in gene responsible for deficiency of lysosomal acid alpha glucosidase enzyme (GAA) for patients with GSD type 2.[3]
- Methods for molecular genetic testing include:
References
- ↑ ACMG Work Group on Management of Pompe Disease. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ; et al. (2006). "Pompe disease diagnosis and management guideline". Genet Med. 8 (5): 267–88. doi:10.109701.gim.0000218152.87434.f3 Check
|doi=
value (help). PMC 3110959. PMID 16702877. - ↑ Ausems MG, Lochman P, van Diggelen OP, Ploos van Amstel HK, Reuser AJ, Wokke JH (1999). "A diagnostic protocol for adult-onset glycogen storage disease type II". Neurology. 52 (4): 851–3. PMID 10078739.
- ↑ Leslie N, Bailey L. Pompe Disease. 2007 Aug 31 [Updated 2017 May 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1261/